Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Equities research analysts at HC Wainwright reduced their Q3 2025 earnings per share estimates for shares of Mind Medicine (MindMed) in a report issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.36) per share for the quarter, down from their previous estimate of ($0.35). HC Wainwright currently has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)'s FY2025 earnings at ($1.32) EPS and FY2027 earnings at ($1.31) EPS.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.01.
Other equities analysts have also recently issued reports about the company. Robert W. Baird reduced their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, March 7th. Cantor Fitzgerald upgraded Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Tuesday, May 13th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Friday, May 9th. Nine equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $25.11.
Read Our Latest Stock Analysis on Mind Medicine (MindMed)
Mind Medicine (MindMed) Stock Performance
Shares of Mind Medicine (MindMed) stock traded down $0.02 during mid-day trading on Monday, hitting $7.24. 182,668 shares of the stock were exchanged, compared to its average volume of 1,385,898. The company has a market capitalization of $545.59 million, a P/E ratio of -3.20 and a beta of 2.52. The company has a 50-day simple moving average of $6.24 and a 200 day simple moving average of $6.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.00 and a current ratio of 9.00. Mind Medicine has a 12 month low of $4.70 and a 12 month high of $10.44.
Hedge Funds Weigh In On Mind Medicine (MindMed)
Institutional investors and hedge funds have recently modified their holdings of the company. Diadema Partners LP purchased a new stake in Mind Medicine (MindMed) during the 4th quarter worth $33,000. Hollencrest Capital Management lifted its stake in shares of Mind Medicine (MindMed) by 10,833.3% during the fourth quarter. Hollencrest Capital Management now owns 7,216 shares of the company's stock worth $50,000 after purchasing an additional 7,150 shares in the last quarter. Black Swift Group LLC purchased a new stake in shares of Mind Medicine (MindMed) in the first quarter worth about $63,000. CreativeOne Wealth LLC acquired a new stake in shares of Mind Medicine (MindMed) in the first quarter valued at about $67,000. Finally, King Wealth Management Group acquired a new stake in shares of Mind Medicine (MindMed) in the fourth quarter valued at about $70,000. Hedge funds and other institutional investors own 27.91% of the company's stock.
Insider Buying and Selling at Mind Medicine (MindMed)
In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 21,208 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the completion of the sale, the chief executive officer now owns 856,556 shares of the company's stock, valued at approximately $5,773,187.44. This trade represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Karlin sold 6,836 shares of the company's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the transaction, the insider now owns 446,177 shares in the company, valued at $3,007,232.98. The trade was a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,391 shares of company stock worth $204,835 over the last three months. Insiders own 2.45% of the company's stock.
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Further Reading
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
